Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06738303 · ClinicalTrials.gov registry record · Phase 2

Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

A Phase 2 study of Metastatic Castration-Resistant Prostate Cancer and Metastatic Prostate Cancer, sponsored by Case Comprehensive Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
44
Enrollment target
1
Study location

NCT06738303: Recruiting Phase 2 study of Metastatic Castration-Resistant Prostate Cancer and Metastatic Prostate Cancer, sponsored by Case Comprehensive Cancer Center.

NCT06738303 is a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer and Metastatic Prostate Cancer that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 44 participants, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06738303, a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer and Metastatic Prostate Cancer, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
44 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to find out what treatment works best for participants with metastatic prostate cancer that are not responding to hormone treatment and docetaxel and are also Prostate-specific membrane antigen(PSMA) positive.

Primary Outcome

PSA decline of ≥50% (PSA50) at 12 weeks. PSA decline will be measured by obtaining the ratio of PSA obtained on cycle 5 day 1 to baseline PSA obtained cycle 1 day 1.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer Metastatic Prostate Cancer

Interventions

  • DRUG Cabazitaxel and carboplatin
  • DRUG Lu-PSMA-617

Study Locations (1)

Ohio

  • Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer Center - Cleveland

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2025-07-14
Est. Completion 2026-12
Phase Phase 2
Case Comprehensive Cancer Center

407 total trials

What NCT06738303 shows while recruiting

NCT06738303 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (78% lower).

The record links to 2 conditions, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cabazitaxel and carboplatin is the first listed.

NCT06738303 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT06738303 about?

NCT06738303 is a clinical study titled "Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer". The purpose of this study is to find out what treatment works best for participants with metastatic prostate cancer that are not responding to hormone treatment and docetaxel and are also Prostate-specific membrane antigen(PSMA) positive.

What is the current status of trial NCT06738303?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2025-07-14. Estimated completion is 2026-12.

What conditions does trial NCT06738303 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer, Metastatic Prostate Cancer.

What interventions are being tested in trial NCT06738303?

The interventions under investigation include: Cabazitaxel and carboplatin (DRUG), Lu-PSMA-617 (DRUG).

Who is sponsoring clinical trial NCT06738303?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06738303 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06738303's enrollment target sits among peer trials

44 46th of 69 higher than 23 of 69 other Metastatic Castration-Resistant Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Castration-Resistant Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323945 · 44 participants · NA

    Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury

  • NCT03093909 · 44 participants · Phase 1

    Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

  • NCT03104491 · 44 participants · Phase 1

    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • NCT03781765 · 44 participants · Phase 4

    Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06738303

Source: ClinicalTrials.gov NCT06738303, the US trial registry maintained by the National Library of Medicine. NCT06738303 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.